148 related articles for article (PubMed ID: 24430674)
1. A high-throughput-compatible FRET-based platform for identification and characterization of botulinum neurotoxin light chain modulators.
Caglič D; Bompiani KM; Krutein MC; Čapek P; Dickerson TJ
J Vis Exp; 2013 Dec; (82):50908. PubMed ID: 24430674
[TBL] [Abstract][Full Text] [Related]
2. Differential endopeptidase activity of different forms of type A botulinum neurotoxin: A unique relationship between the size of the substrate and activity of the enzyme.
Ambrin G; Kumar R; Singh BR
Toxicon; 2018 Mar; 144():34-41. PubMed ID: 29309744
[TBL] [Abstract][Full Text] [Related]
3. 8-Hydroxyquinoline and hydroxamic acid inhibitors of botulinum neurotoxin BoNT/A.
Dickerson TJ; Smith GR; Pelletier JC; Reitz AB
Curr Top Med Chem; 2014; 14(18):2094-102. PubMed ID: 25335884
[TBL] [Abstract][Full Text] [Related]
4. Natural Compounds and Their Analogues as Potent Antidotes against the Most Poisonous Bacterial Toxin.
Patel KB; Cai S; Adler M; Singh BK; Parmar VS; Singh BR
Appl Environ Microbiol; 2018 Dec; 84(24):. PubMed ID: 30389764
[TBL] [Abstract][Full Text] [Related]
5. Interactions of a potent cyclic peptide inhibitor with the light chain of botulinum neurotoxin A: Insights from X-ray crystallography.
Kumaran D; Adler M; Levit M; Krebs M; Sweeney R; Swaminathan S
Bioorg Med Chem; 2015 Nov; 23(22):7264-73. PubMed ID: 26522088
[TBL] [Abstract][Full Text] [Related]
6. A high content imaging assay for identification of Botulinum neurotoxin inhibitors.
Kota KP; Soloveva V; Wanner LM; Gomba G; Kiris E; Panchal RG; Kane CD; Bavari S
J Vis Exp; 2014 Nov; (93):e51915. PubMed ID: 25489815
[TBL] [Abstract][Full Text] [Related]
7. Strategies to Counteract Botulinum Neurotoxin A: Nature's Deadliest Biomolecule.
Lin L; Olson ME; Eubanks LM; Janda KD
Acc Chem Res; 2019 Aug; 52(8):2322-2331. PubMed ID: 31322847
[TBL] [Abstract][Full Text] [Related]
8. Tandem fluorescent proteins as enhanced FRET-based substrates for botulinum neurotoxin activity.
Pires-Alves M; Ho M; Aberle KK; Janda KD; Wilson BA
Toxicon; 2009 Mar; 53(4):392-9. PubMed ID: 19168088
[TBL] [Abstract][Full Text] [Related]
9. High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
Saunders MJ; Graves SW; Sklar LA; Oprea TI; Edwards BS
Assay Drug Dev Technol; 2010 Feb; 8(1):37-46. PubMed ID: 20035615
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in botulinum neurotoxin inhibitor development.
Kiris E; Burnett JC; Kane CD; Bavari S
Curr Top Med Chem; 2014; 14(18):2044-61. PubMed ID: 25335887
[TBL] [Abstract][Full Text] [Related]
11. High-throughput screening technologies for botulinum neurotoxins.
Bompiani KM; Dickerson TJ
Curr Top Med Chem; 2014; 14(18):2062-80. PubMed ID: 25335886
[TBL] [Abstract][Full Text] [Related]
12. Post-intoxication inhibition of botulinum neurotoxin serotype A within neurons by small-molecule, non-peptidic inhibitors.
Ruthel G; Burnett JC; Nuss JE; Wanner LM; Tressler LE; Torres-Melendez E; Sandwick SJ; Retterer CJ; Bavari S
Toxins (Basel); 2011 Mar; 3(3):207-17. PubMed ID: 22069707
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of botulinum neurotoxin BoNT/A.
Dickerson TJ; Smith GR; Reitz AB
Curr Top Med Chem; 2014; 14(18):2043. PubMed ID: 25335883
[No Abstract] [Full Text] [Related]
14. High-Throughput Screening Uncovers Novel Botulinum Neurotoxin Inhibitor Chemotypes.
Bompiani KM; Caglič D; Krutein MC; Benoni G; Hrones M; Lairson LL; Bian H; Smith GR; Dickerson TJ
ACS Comb Sci; 2016 Aug; 18(8):461-74. PubMed ID: 27314875
[TBL] [Abstract][Full Text] [Related]
15. Embryonic stem cell-derived motoneurons provide a highly sensitive cell culture model for botulinum neurotoxin studies, with implications for high-throughput drug discovery.
Kiris E; Nuss JE; Burnett JC; Kota KP; Koh DC; Wanner LM; Torres-Melendez E; Gussio R; Tessarollo L; Bavari S
Stem Cell Res; 2011 May; 6(3):195-205. PubMed ID: 21353660
[TBL] [Abstract][Full Text] [Related]
16. An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists.
Eubanks LM; Hixon MS; Jin W; Hong S; Clancy CM; Tepp WH; Baldwin MR; Malizio CJ; Goodnough MC; Barbieri JT; Johnson EA; Boger DL; Dickerson TJ; Janda KD
Proc Natl Acad Sci U S A; 2007 Feb; 104(8):2602-7. PubMed ID: 17293454
[TBL] [Abstract][Full Text] [Related]
17. Probing BoNT/A protease exosites: implications for inhibitor design and light chain longevity.
Xue S; Javor S; Hixon MS; Janda KD
Biochemistry; 2014 Nov; 53(43):6820-4. PubMed ID: 25295706
[TBL] [Abstract][Full Text] [Related]
18. Development of cell-based assays to measure botulinum neurotoxin serotype A activity using cleavage-sensitive antibodies.
Nuss JE; Ruthel G; Tressler LE; Wanner LM; Torres-Melendez E; Hale ML; Bavari S
J Biomol Screen; 2010 Jan; 15(1):42-51. PubMed ID: 19965805
[TBL] [Abstract][Full Text] [Related]
19. Mastoparan-7 rescues botulinum toxin-A poisoned neurons in a mouse spinal cord cell culture model.
Zhang P; Ray R; Singh BR; Ray P
Toxicon; 2013 Dec; 76():37-43. PubMed ID: 24047963
[TBL] [Abstract][Full Text] [Related]
20. Development of a fluorescence internal quenching correction factor to correct botulinum neurotoxin type A endopeptidase kinetics using SNAPtide.
Feltrup TM; Singh BR
Anal Chem; 2012 Dec; 84(24):10549-53. PubMed ID: 23181535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
